High‐resolution mass spectrometry‐based approach for the identification and profiling of the metabolites of taletrectinib formed in liver microsomes. Issue 6 (8th February 2021)

• Record Type: Journal Article
• Authors: Ye, Yongbin; Guo, Xiaojuan; He, Xin; Zhang, Mingwan; He, Huiqing; Qiu, Dafa; Guo, Ziwen
• Is Part Of: Drug testing and analysis. Volume 13:Issue 6(2021)
• Page Start: 1118
• Page End: 1126
• Publication Date: 2021-02-08
• Subjects: liver microsomes -- metabolic pathways -- metabolite identification -- Taletrectinib; Drugs -- Analysis -- Periodicals; Drug testing -- Periodicals; Chemistry, Forensic -- Periodicals; 615.1901
• DOI: 10.1002/dta.3008
• Languages: English
• ISSNs: 1942-7603

Abstract

Abstract: Taletrectinib is a potent, orally active, and selective ROS1/NTRK kinase inhibitor. The aim of this study was to study the metabolism of taletrectinib in rat, dog, and human liver microsomes. The biotransformation of taletrectinib was carried out using rat, dog, and human liver microsomes supplemented with nicotinamide adenine dinucleotide phosphate tetrasodium salt (NADPH) and uridine diphosphate glucuronic acid (UDPGA). The microsomal incubations were conducted at 37°C for 60 min. The formed metabolites were identified by ultrahigh performance liquid chromatography coupled to high‐resolution tandem mass spectrometry (UHPLC‐HRMS) using electrospray ionization in the positive ion mode. They were identified by accurate masses and MS/MS spectra and based on their fragmentation pathways. With UHPLC‐HRMS, a total of 10 metabolites including one glucuronide conjugate (M7) were structurally identified. M9 and M10 were unambiguously identified as taletrectinib alcohol and taletrectinib ketone, respectively, using reference standards. The phase I metabolic pathways of taletrectinib involved N ‐dealkylation, O ‐dealkylation, oxidative deamination, and oxygenation; the phase II metabolic pathways referred to glucuronidation. The current study investigated the in vitro metabolic fate of taletrectinib in animals and human species, which would bring us considerable benefits for the subsequent studies focusing on the pharmacological effect and toxicity of this drug. Abstract : Taletrectinib is a selective ROS1/NTRK kinase inhibitor. The present work evaluated the in vitro metabolism of taletrectinib in rat, dog, and human liver microsomes. Dealkylation, deamination, oxygenation, and glucuronidation were the major metabolic pathways.